- Home
- ASMB vs FBRX Comparison
ASMB vs FBRX Comparison
Compare ASMB & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- FBRX
- Stock Information
- Founded
- ASMB 2005
- FBRX N/A
- Country
- ASMB United States
- FBRX United States
- Employees
- ASMB 73
- FBRX N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- ASMB Health Care
- FBRX Health Care
- Exchange
- ASMB Nasdaq
- FBRX Nasdaq
- Market Cap
- ASMB 198.6M
- FBRX 154.5M
- IPO Year
- ASMB 2010
- FBRX N/A
- Fundamental
- Price
- ASMB $25.50
- FBRX $11.23
- Analyst Decision
- ASMB Strong Buy
- FBRX Strong Buy
- Analyst Count
- ASMB 4
- FBRX 3
- Target Price
- ASMB $38.67
- FBRX $68.00
- AVG Volume (30 Days)
- ASMB 147.2K
- FBRX 72.7K
- Earning Date
- ASMB 08-06-2025
- FBRX 08-14-2025
- Dividend Yield
- ASMB N/A
- FBRX N/A
- EPS Growth
- ASMB N/A
- FBRX N/A
- EPS
- ASMB N/A
- FBRX N/A
- Revenue
- ASMB $33,247,000.00
- FBRX N/A
- Revenue This Year
- ASMB $12.44
- FBRX N/A
- Revenue Next Year
- ASMB N/A
- FBRX N/A
- P/E Ratio
- ASMB N/A
- FBRX N/A
- Revenue Growth
- ASMB 54.77
- FBRX N/A
- 52 Week Low
- ASMB $7.75
- FBRX $4.11
- 52 Week High
- ASMB $27.17
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- ASMB 65.04
- FBRX 52.47
- Support Level
- ASMB $24.98
- FBRX $10.73
- Resistance Level
- ASMB $27.17
- FBRX $12.50
- Average True Range (ATR)
- ASMB 1.13
- FBRX 1.00
- MACD
- ASMB -0.06
- FBRX 0.03
- Stochastic Oscillator
- ASMB 64.24
- FBRX 35.48
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).